Sökning: ((WFRF:(Huovinen Riikka)))
> (2022) >
Adjuvant Capecitabi...
Adjuvant Capecitabine for Early Breast Cancer : 15-Year Overall Survival Results From a Randomized Trial
-
- Joensuu, Heikki (författare)
- Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.
-
- Kellokumpu-Lehtinen, Pirkko-Liisa (författare)
- Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland.
-
- Huovinen, Riikka (författare)
- Turku Univ Hosp, Dept Oncol, Turku, Finland.
-
visa fler...
-
- Jukkola, Arja (författare)
- Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland.;Oulu Univ Hosp, Dept Radiotherapy & Oncol, Oulu, Finland.
-
- Tanner, Minna (författare)
- Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland.
-
- Ahlgren, Johan (författare)
- Gävle Cent Hosp, Gävle, Sweden.;Acad Hosp, Reg Canc Ctr Mid Sweden, Uppsala, Sweden.
-
- Auvinen, Päivi (författare)
- Kuopio Univ Hosp, Ctr Canc, Kuopio, Finland.
-
- Lahdenperä, Outi (författare)
- Turku Univ Hosp, Dept Oncol, Turku, Finland.
-
- Villman, Kenneth (författare)
- Örebro Univ Hosp, Örebro, Sweden.
-
- Nyandoto, Paul (författare)
- Paijat Hame Cent Hosp, Lahti, Finland.
-
- Nilsson, Greger (författare)
- Uppsala universitet,Experimentell och klinisk onkologi,Gävle Cent Hosp, Dept Oncol, Sweden.;Visby Hosp, Sweden.
-
- Poikonen-Saksela, Paula (författare)
- Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.
-
- Kataja, Vesa (författare)
- Cent Finland Cent Hosp, Jyvaskyla, Finland.
-
- Bono, Petri (författare)
- Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.
-
- Junnila, Jouni (författare)
- EstiMates, Turku, Finland.
-
- Lindman, Henrik (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
visa färre...
-
Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland;Univ Helsinki, Helsinki, Finland. Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland. (creator_code:org_t)
- American Society of Clinical Oncology (ASCO), 2022
- 2022
- Engelska.
-
Ingår i: Journal of Clinical Oncology. - : American Society of Clinical Oncology (ASCO). - 0732-183X .- 1527-7755. ; 40:10, s. 1051-1058
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer.METHODS: The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates integration of capecitabine to an adjuvant chemotherapy regimen containing a taxane and an anthracycline for the treatment of early breast cancer. Between January 27, 2004, and May 29, 2007, 1,500 patients with axillary node-positive or high-risk node-negative early breast cancer were accrued. The patients were randomly allocated to either TX-CEX, consisting of three cycles of docetaxel (T) plus capecitabine (X) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX, 753 patients), or to T-CEF, consisting of three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF, 747 patients). We performed a protocol-scheduled analysis of overall survival on the basis of approximately 15-year follow-up of the patients.RESULTS: The data collection was locked on December 31, 2020. By this date, the median follow-up time of the patients alive was 15.3 years (interquartile range, 14.5-16.1 years) in the TX-CEX group and 15.4 years (interquartile range, 14.8-16.0 years) in the T-CEF group. Patients assigned to TX-CEX survived longer than those assigned to T-CEF (hazard ratio 0.81; 95% CI, 0.66 to 0.99; P = .037). The 15-year survival rate was 77.6% in the TX-CEX group and 73.3% in the T-CEF group. In exploratory subgroup analyses, patients with estrogen receptor-negative cancer and those with triple-negative cancer treated with TX-CEX tended to live longer than those treated with T-CEF.CONCLUSION: Addition of capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Joensuu, Heikki
-
Kellokumpu-Lehti ...
-
Huovinen, Riikka
-
Jukkola, Arja
-
Tanner, Minna
-
Ahlgren, Johan
-
visa fler...
-
Auvinen, Päivi
-
Lahdenperä, Outi
-
Villman, Kenneth
-
Nyandoto, Paul
-
Nilsson, Greger
-
Poikonen-Saksela ...
-
Kataja, Vesa
-
Bono, Petri
-
Junnila, Jouni
-
Lindman, Henrik
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Uppsala universitet